ERAS250117C2000
- 0.65
- 0.000.00%
Erasca Newsroom
Oncology in Focus: How Emerging Therapies Are Reshaping Cancer Treatment
Clear Street Launches Healthcare & Biotechnology Equity Research
Stellantis, PG&E And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Jefferies Initiates Erasca(ERAS.US) With Buy Rating, Announces Target Price $6
Erasca Initiated at Buy by Jefferies
Express News | Erasca Inc : Guggenheim Raises Target Price to $3.5 From $3
BofA Securities Maintains Erasca(ERAS.US) With Hold Rating
Bank of America Securities Sticks to Its Hold Rating for Erasca (ERAS)
Erasca, Inc. Reports Strong Progress in Oncology Pipeline
Morgan Stanley Maintains Erasca(ERAS.US) With Buy Rating, Maintains Target Price $4
H.C. Wainwright Maintains Erasca(ERAS.US) With Buy Rating, Maintains Target Price $6
Erasca's Innovative Naporafenib Shows Promise in NRAS-mutant Melanoma, Garnering Buy Rating From Analyst
Erasca | 10-Q: Q3 2024 Earnings Report
Erasca | 8-K: Erasca Reports Third Quarter 2024 Business Updates and Financial Results
Erasca Reports Q3 EPS (11c), Consensus (17c)
Erasca 3Q Loss/Shr 11c >ERAS
Earnings Flash (ERAS) ERASCA Posts Q3 Loss $-0.11
Express News | Erasca Reports Third Quarter 2024 Business Updates and Financial Results
Express News | Erasca Q3 Operating Income USD -37.242 Million
Erasca to Present at Upcoming Investor Conferences